<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499265</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000553460</org_study_id>
    <secondary_id>WILEX-WX-60-004</secondary_id>
    <nct_id>NCT00499265</nct_id>
  </id_info>
  <brief_title>Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Randomized, Open Label, Phase II Proof of Concept Study of WX-671 in Combination With Gemcitabine vs.Gemcitabine Alone in Patients With Locally Advanced, Non Resectable Pancreatic Cancer in Order to Evaluate the Anti-Tumor Activity of the Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      WX-671 may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. Giving gemcitabine together with WX-671 may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well gemcitabine works when given&#xD;
      together with WX-671 or when given alone in treating patients with locally advanced&#xD;
      pancreatic cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the antitumor activity of two different doses of anti-uPA serine protease&#xD;
           inhibitor WX-671 when given in combination with gemcitabine hydrochloride in patients&#xD;
           with locally advanced unresectable pancreatic cancer.&#xD;
&#xD;
        -  Compare the efficacy, in terms of response rate, progression-free survival, time to&#xD;
           first metastasis, overall survival, and tumor and uPA system-related markers, of these&#xD;
           regimens in these patients.&#xD;
&#xD;
        -  Compare the safety, in terms of vital signs, ECG, biochemistry, hematology (including&#xD;
           coagulation), and adverse events, of these regimens.&#xD;
&#xD;
      OUTLINE: This is an open-label, randomized, multicenter study. Patients are randomized to 1&#xD;
      of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive of oral anti-uPA serine protease inhibitor WX-671 once daily in&#xD;
           weeks 1-8 (weeks 1-4 of each subsequent course) and gemcitabine hydrochloride IV over 30&#xD;
           minutes once weekly in weeks 1-7 (weeks 1-3 of each subsequent course) of course 1. All&#xD;
           subsequent courses repeat every 4 weeks in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral anti-uPA serine protease inhibitor WX-671 (at a lower dose&#xD;
           than in arm I) once daily in weeks 1-8 (weeks 1-4 of each subsequent course) and&#xD;
           gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 1-7 (weeks 1-3 of each&#xD;
           subsequent course) of course 1. All subsequent courses repeat every 4 weeks in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm III: Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly in&#xD;
           weeks 1-7 (weeks 1-3 of each subsequent course) of course 1. All subsequent courses&#xD;
           repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy, in terms of response rate, progression-free survival, time to first metastasis, overall survival, and tumor and uPA system-related markers</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine plus 200 mg WX-671</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine plus 400 mg WX-671</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks</description>
    <arm_group_label>Gemcitabine</arm_group_label>
    <other_name>GEMZAR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serine Proteinase Inhibitor WX-671</intervention_name>
    <description>oral, daily</description>
    <arm_group_label>Gemcitabine plus 200 mg WX-671</arm_group_label>
    <other_name>MESUPRON</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serine Proteinase Inhibitor WX-671</intervention_name>
    <description>oral, daily</description>
    <arm_group_label>Gemcitabine plus 400 mg WX-671</arm_group_label>
    <other_name>MESUPRON</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Inclusion criteria:&#xD;
&#xD;
               -  Locally advanced, unresectable, non-metastatic, histologically proven pancreatic&#xD;
                  adenocarcinoma (lymph nodes will not be considered metastases)&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               -  Any distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Inclusion criteria:&#xD;
&#xD;
               -  ECOG performance status ≤ 1&#xD;
&#xD;
               -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
               -  Normal 12-lead ECG or only clinically insignificant abnormalities in the judgment&#xD;
                  of the investigator&#xD;
&#xD;
               -  Female patients of child-bearing potential will be required to use an effective&#xD;
                  method of birth control for the duration of the study to prevent pregnancy&#xD;
&#xD;
               -  ANC ≥ 1,500/mm³&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
               -  Creatinine ≤ 2 times ULN or creatinine clearance &gt; 45 mL/min&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               -  History of or current primary blood coagulation or bleeding disorders such as&#xD;
                  hemophilia&#xD;
&#xD;
               -  Any unrelated illness, e.g., active infection, inflammation, medical condition or&#xD;
                  laboratory abnormalities, which in the judgment of the investigator might&#xD;
                  significantly affect the patient's study participation&#xD;
&#xD;
               -  Any surgical or medical condition that might significantly alter the absorption,&#xD;
                  distribution, metabolism or excretion of any drug&#xD;
&#xD;
               -  Significant cardiac insufficiency (NYHA classification III or IV), presence of&#xD;
                  unstable angina or myocardial infarction within the previous 6 months, use of&#xD;
                  ongoing maintenance therapy for life threatening arrhythmia or known pulmonary&#xD;
                  hypertension&#xD;
&#xD;
               -  Any secondary malignancies within the last 5 years except for surgically cured&#xD;
                  non-melanoma skin cancer or cervical carcinoma in situ&#xD;
&#xD;
               -  Pregnancy (positive serum pregnancy test) or lactation&#xD;
&#xD;
               -  Known hepatitis B/C or HIV infection&#xD;
&#xD;
               -  Known hypersensitivity to any of the components in the anti-uPA serine protease&#xD;
                  inhibitor WX-671 capsules or gemcitabine hydrochloride infusion or other medical&#xD;
                  reasons for not being able to receive adequate pre-medication (for example,&#xD;
                  antihistamine or anti-inflammatory agents)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Permitted:&#xD;
&#xD;
               -  Growth factors for treatment (not prophylaxis, i.e., epoetin alfa), analgesics,&#xD;
                  blood transfusions, antibiotics, bisphosphonates, other hormonal therapy for&#xD;
                  contraceptive practice, replacement therapy such as thyroid replacement or&#xD;
                  adrenal insufficiency as appropriate and medications for acute or chronic&#xD;
                  conditions not listed under the exclusion criteria&#xD;
&#xD;
               -  Embolization (i.e. for hematuria)&#xD;
&#xD;
               -  Subjects can receive blood transfusions as medically appropriate during the study&#xD;
&#xD;
                    -  Subjects who require a blood transfusion during screening must have stable&#xD;
                       hemoglobin (≥9.0 g/dL [5.6 mmol/L]) without the need for further&#xD;
                       transfusions within 2 weeks before the first dose of anti-uPA serine&#xD;
                       protease inhibitor WX-671 to remain eligible&#xD;
&#xD;
               -  Prophylactic use of growth factors to support neutrophils&#xD;
&#xD;
          -  Prohibited:&#xD;
&#xD;
               -  Anticoagulant or thrombolytic therapy within four weeks prior to start of&#xD;
                  treatment (except low dose anticoagulant therapy with unfractionated heparin ≤&#xD;
                  15000 IU/d, low molecular weight heparin ≤ 5000 IE anti-Xa activity or acetyl&#xD;
                  salicylic acid ≤ 100 mg/d at the discretion of the investigator)&#xD;
&#xD;
               -  Anticancer therapies such as biologic therapy and chemotherapy (other than study&#xD;
                  drugs)&#xD;
&#xD;
               -  Radiation therapy (during the treatment phase of the protocol; increased bone&#xD;
                  pain not controlled by medication and requiring palliative therapy will be&#xD;
                  considered disease progression)&#xD;
&#xD;
               -  Laser treatment&#xD;
&#xD;
               -  Any other investigational agent&#xD;
&#xD;
               -  Thalidomide&#xD;
&#xD;
               -  Immunosuppressive therapies (inhaled or replacement dose corticosteroids are&#xD;
                  permitted).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carola Mala, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heidelberg Pharma AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite University Hospital - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-Meyerhof-Zentrum Tagesklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Medizinische Klinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Muenchen Bogenhausen</name>
      <address>
        <city>Munich</city>
        <zip>D-81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Laszlo Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Onkologiai Tanzek</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar County Hospital</name>
      <address>
        <city>Gydr</city>
        <zip>h-9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs Faculty of Medicine</name>
      <address>
        <city>Pecs</city>
        <zip>H-7643</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szeged University</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Livorno</name>
      <address>
        <city>Livorno</city>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori/Fondazione Pascale</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Filippo Neri</name>
      <address>
        <city>Rome</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altai Oncology Center</name>
      <address>
        <city>Barnaul</city>
        <zip>656049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Oncology Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>109033</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Academy of Medical Sciences Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov Research Institute of Oncology - Omsk</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov State Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Cruz i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico M.D. Anderson International Espana</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkassy Regional Oncology Center</name>
      <address>
        <city>Cherkassy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bukovinian State Medical University</name>
      <address>
        <city>Chernivtsy</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk State Medical Academy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk Regional Antitumor Center</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankovsk Regional Oncology Center</name>
      <address>
        <city>Ivano-Frankovsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grigoriev Institute for Radiology Academy of Medical Science of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Kiev</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ukrainian Medical Stomatological Academy</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>March 28, 2012</last_update_submitted>
  <last_update_submitted_qc>March 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Serine Proteinase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

